313 related articles for article (PubMed ID: 7833230)
1. Lansoprazole does not affect the bioavailability of oral contraceptives.
Fuchs W; Sennewald R; Klotz U
Br J Clin Pharmacol; 1994 Oct; 38(4):376-80. PubMed ID: 7833230
[TBL] [Abstract][Full Text] [Related]
2. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.
London RS; Chapdelaine A; Upmalis D; Olson W; Smith J
Acta Obstet Gynecol Scand Suppl; 1992; 156():9-14. PubMed ID: 1324557
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic interaction of solifenacin with an oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women: a double-blind, placebo-controlled study.
Taekema-Roelvink ME; Swart PJ; Kuipers ME; Krauwinkel WJ; Visser N; Smulders RA
Clin Ther; 2005 Sep; 27(9):1403-10. PubMed ID: 16291413
[TBL] [Abstract][Full Text] [Related]
4. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives.
Aden U; Jung-Hoffmann C; Kuhl H
Contraception; 1998 Aug; 58(2):75-81. PubMed ID: 9773261
[TBL] [Abstract][Full Text] [Related]
5. An investigation into the effect of tenidap sodium on the pharmacokinetics of a combined oral contraceptive.
Coates PE; Mesure R
Br J Clin Pharmacol; 1995; 39 Suppl 1(Suppl 1):47S-50S. PubMed ID: 7547095
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of levonorgestrel and ethinylestradiol in 9 women who received a low-dose oral contraceptive over a treatment period of 3 months and, after a wash-out phase, a single oral administration of the same contraceptive formulation.
Kuhnz W; al-Yacoub G; Fuhrmeister A
Contraception; 1992 Nov; 46(5):455-69. PubMed ID: 1458892
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Staks T; Jütting G
Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
[TBL] [Abstract][Full Text] [Related]
8. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel.
Gaspard UJ; Romus MA; Gillain D; Duvivier J; Demey-Ponsart E; Franchimont P
Contraception; 1983 Jun; 27(6):577-90. PubMed ID: 6225622
[TBL] [Abstract][Full Text] [Related]
9. No interacting influence of lavender oil preparation silexan on oral contraception using an ethinyl estradiol/levonorgestrel combination.
Heger-Mahn D; Pabst G; Dienel A; Schläfke S; Klipping C
Drugs R D; 2014 Dec; 14(4):265-72. PubMed ID: 25319228
[TBL] [Abstract][Full Text] [Related]
10. Ovarian activity during regular oral contraceptive use.
Crosignani PG; Testa G; Vegetti W; Parazzini F
Contraception; 1996 Nov; 54(5):271-3. PubMed ID: 8934059
[TBL] [Abstract][Full Text] [Related]
11. The effects of ampicillin on oral contraceptive steroids in women.
Back DJ; Breckenridge AM; MacIver M; Orme M; Rowe PH; Staiger C; Thomas E; Tjia J
Br J Clin Pharmacol; 1982 Jul; 14(1):43-8. PubMed ID: 6809025
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
Carlström K; Lunell NO; Zador G
Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
[TBL] [Abstract][Full Text] [Related]
13. Effect of low-dose oral contraceptives on androgenic markers and acne.
Thorneycroft IH; Stanczyk FZ; Bradshaw KD; Ballagh SA; Nichols M; Weber ME
Contraception; 1999 Nov; 60(5):255-62. PubMed ID: 10717776
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a new triphasic oral contraceptive in private practice.
Ellsworth HS; Ayerst RI; Harris JW; Stone RA; Anderson AE; Jones TL; Curtis MK
Contraception; 1986 Nov; 34(5):435-42. PubMed ID: 3102161
[TBL] [Abstract][Full Text] [Related]
15. The relative bioavailability of levonorgestrel and ethinyl estradiol administered as a low-dose combination oral contraceptive.
Goebelsmann U; Hoffman D; Chiang S; Woutersz T
Contraception; 1986 Oct; 34(4):341-51. PubMed ID: 3096634
[TBL] [Abstract][Full Text] [Related]
16. The lack of interaction between temafloxacin and combined oral contraceptive steroids.
Back DJ; Tjia J; Martin C; Millar E; Mant T; Morrison P; Orme M
Contraception; 1991 Apr; 43(4):317-23. PubMed ID: 1906791
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens.
Vandever MA; Kuehl TJ; Sulak PJ; Witt I; Coffee A; Wincek TJ; Reape KZ
Contraception; 2008 Mar; 77(3):162-70. PubMed ID: 18279685
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
Endrikat J; Blode H; Gerlinger C; Rosenbaum P; Kuhnz W
Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
[TBL] [Abstract][Full Text] [Related]
20. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol.
Goebelsmann U; Mashchak CA; Mishell DR
Am J Obstet Gynecol; 1985 Apr; 151(7):868-77. PubMed ID: 3920910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
